DeLiver Pharma ApS: Financial statements 2022
CVR: 39432714
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
DeLiver Pharma ApS (CVR 39432714) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -17,951 and a net result of DKK -29,331 compared with DKK -146,911 the year before. Equity in the 2022 report amounted to DKK 109,487. The solvency ratio was 90.7%.
- Gross Profit
- DKK -17,951
- Profit/Loss
- DKK -29,331
- Equity
- DKK 109,487
- Total Assets
- DKK 120,750
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -18K | -29K | 109K | - |
| 2021 | - | -22K | -147K | 139K | - |
| 2020 | - | -20K | -114K | 246K | - |
| 2019 | 79K | 51K | -12K | 220K | - |
Official annual report
Keep an eye on DeLiver Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
DeLiver Pharma ApS has published its annual report for 2021. Gross profit came to DKK -21,884, and the net result was DKK -146,911.
About DeLiver Pharma ApS
DeLiver Pharma ApS is a Danish company of the type Anpartsselskab based in Faaborg, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Niels Jonas Heilskov Graversen. The board consists of Jens Kristian Damsgaard (chair), Holger Jon Møller, Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. The company's owners include MOESTRUP HOLDING 2007 ApS, MØLLER HOLDING 2007 ApS and PHIDEAS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -20,487 and a net result of DKK -31,867 compared with DKK -21,682 the year before. Equity in the 2025 report amounted to DKK 163,221.